65864 Federal Register / Vol. 65, No. 213 / Thursday, November 2, 2000 / Notices

that an intact polo-box is required for

this event. These data raise an intriguing

possibility that conditional expression

of the polo-box domain may selectively

inhibit the mitotic functions of polo

kinases. Furthermore, our observation

suggests that the polo-box peptide may

act as a potential anti-cancer therapeutic

agent. Alternatively, isolation of small

chemical compounds that bind to the

polo-box and interfere with its function

may yield a strategy to regulate highly

proliferative malignant cells. We have

developed two yeast strains that

conditionally express the polo-box

domains of Plk (KLY1212) or Cdc5

(KLY1083). Isolation of chemical

compounds alleviating the dominantnegative cell division defect of these

strains may lead to identification of

polo-box inhibitors. Since the polo-box

is an essential and unique domain for

polo kinases, these inhibitors may likely

provide selective tools to control the

cell proliferation without interfering

with other protein kinases.

The described methods are the subject

of a U.S. provisional patent application

filed May 23, 2000 by the Public Health

Service on behalf of the Federal

Government. Furthermore, the initial

report and characterization of the

invention is described in: Song S, and

Lee KS. A novel function of

Saccharomyces cerevisiae CDC5 in

cytokinesis (submitted for publication).

Further reference to the invention can

be found in: (1) Song S, Grenfell TX,

Garfield S, Erikson RL, and Lee KS.

(2000). Essential function of the polobox of Cdc5 in subcellular localization

and induction of cytokinetic structures.

Mol. Cell. Biol. 20, 286–298, and (2) Lee

KS, Grenfell TZ Yarm, FR, and Erikson

RL (1998). Mutation of the polo-box

disrupts localization and mitotic

functions of the mammalian polo kinase

Plk. Proc. Natl. Acad. Sci. USA

95:9301–9306.

Under the present proposal, the goal

of the CRADA will involve the

following:

(1) Identification and isolation of

chemical compounds that alleviate the

dominant-negative cell division defect

of yeast strains that conditionally

express the polo-box domains of Plk or

Cdc5.

(2) Development of these chemical

compounds as tools to control cellular

proliferation without interfering with

other protein kinases.

Party Contributions

The role of the NCI in the CRADA

may include, but not be limited to:

1. Providing intellectual, scientific,

and technical expertise and experience

to the research project.

2. Providing the CRADA Collaborator

with information and data relating to

polo kinases.

3. Planning research studies and

interpreting research results.

4. Carrying out research with

validates and expands on the role of the

dominant-negative inhibition of cell

proliferation found using the intact

polo-box.

5. Publishing research results.

6. Developing additional potential

applications related to inhibition of cell

proliferation using polo-box inhibitors.

The role of the CRADA Collaborator

may include, but not be limited to:

1. Providing significant intellectual,

scientific, and technical expertise or

experience to the research project.

2. Planning research studies and

interpreting research results.

3. Providing technical and/or

financial support to facilitate scientific

goals and for further design of

applications of the technology outlined

in the agreement.

4. Publishing research results.

Selection criteria for choosing the

CRADA Collaborator may include, but

not be limited to:

1. A demonstrated record of success

in the areas of isolation, purification,

characterization, and therapeutic

development of chemical compounds.

2. A demonstrated background and

expertise in cancer-related sciences.

3. The ability to collaborate with NCI

on further research and development of

this technology. This ability will be

demonstrated through experience and

expertise in this or related areas of

technology indicating the ability to

contribute intellectually to ongoing

research and development.

4. The demonstration of adequate

resources to perform the research and

development of this technology (e.g.

facilities, personnel and expertise) and

to accomplish objectives according to an

appropriate timetable to be outlined in

the CRADA Collaborator’s proposal.

5. The willingness to commit best

effort and demonstrated resources to the

research and development of this

technology, as outlined in the CRADA

Collaborator’s proposal.

6. The demonstration of expertise in

the commercial development and

production of products related to this

area of technology.

7. The level of financial support the

CRADA Collaborator will provide for

CRADA-related Government activities.

8. The willingness to cooperate with

the national Cancer Institute in the

timely publication of research results.

9. The agreement to be bound by the

appropriate DHHS regulations relating

to human subjects, and all PHS policies

relating to the use and care of laboratory

animals.

10. The willingness to accept the legal

provisions and language of the CRADA

with only minor modifications, if any.

These provisions govern the distribution

of future patent rights to CRADA

inventions. Generally, the rights of

ownership are retained by the

organization that is the employer of the

inventor, with (1) the grant of a license

for research and other Government

purposes to the Government when the

CRADA Collaborator’s employee is the

sole inventor, or (2) the grant of an

option to elect an exclusive or

nonexclusive license to the CRADA

Collaborator when the Government

employee is the sole inventor.

Dated: October 17, 2000.

Kathleen Sybert,

Chief, Technology Development and

Commercialization Branch, National Cancer

Institute, National Institutes of Health.

[FR Doc. 00–28120 Filed 11–1–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute, Notice of

Closed Meeting.

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

President’s Cancer Panel.

The meeting will be closed to the

public in accordance with the

provisions set forth in section

552b(c)(9)(B), Title 5 U.S.C., as amended

because the premature disclosure of

other and the discussions would likely

to significantly frustrate implementation

of recommendations.

Name of Committee: President’s Cancer

Panel.

Date: October 26, 2000.

Time: 4 pm to 6 pm.

Agenda: To review and evaluate other.

Place: National Institutes of Health, 31

Center Drive, Building 31, Room 4A48,

Bethesda, MD 20892–2473 (Telephone

Conference Call).

Contact Person: Maureen O. Wilson, Phd,

Executive Secretary, National Cancer

Institute, National Institutes of Health, 31

Center Drive, Building 31, Room 4A48,

Bethesda, MD 20892, 301/496–1148.

This notice is being published less than 15

days to the meeting due to scheduling

conflicts.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Federal Register / Vol. 65, No. 213 / Thursday, November 2, 2000 / Notices 65865

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: October 25, 2000.

LaVerne Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–28104 Filed 11–1–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health,

National Cancer Institute; Notice of

Closed Meeting.

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel Molecular

Target Drug Discovery For Cancer:

Exploratory Grants.

Date: November 29–December 1, 2000.

Time: 6:30 pm to 9:00 pm.

Agenda: To review and evaluate grant

applications.

Place: Double Tree Hotel, 1750 Rockville

Pike, Rockville, MD 20852.

Contact Person: Thomas M. Vollberg, PHD,

Scientific Review Administrator, Special

Review, Referral and Resources Branch,

Division of Extramural Activities, National

Cancer Institute, National Institute of Health,

6116 Executive Boulevard, Room 8049,

Rockville, MD 20852, 301/594–9582.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: October 25, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–28106 Filed 11–01–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended

Notice of Meeting

Notice is hereby given of a change in

the meeting of the National Cancer

Institute Special Emphasis Panel,

November 6, 2000, 8 AM to November

6, 2000, 6 PM, National Cancer Institute,

6120 Executive Boulevard, Conference

Room J. Rockville, MD, 20852 which

was published in the Federal Register

on October 19, 2000, 65 FR 62738.

The meeting will be held on

November 9, 2000 from 8 AM to 6 PM.

The meeting is closed to the public.

Dated: October 25, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–28107 Filed 11–01–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in section 552b(c)(4)

and 552b(c)(6), title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Child Health and Human Development

Special Emphasis Panel Neurobiology and

Genetics of Fragile X Syndrome.

Date: November 14–15, 2000.

Time: 8:00 am to 5:00 pm.

Agenda: To review and evaluate grant

applications.

Place: Georgetown Suites, 1000 29th Street,

NW., Washington, DC 20007.

Contact Person: Norman Chang, PhD,

Scientific Review Administrator, Division of

Scientific Review, National Institute of Child

Health, and Human Development, National

Institutes of Health, 6100 Executive Blvd.,

Room 5E03, Bethesda, MD 20892, (301) 496–

1485.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.209, Contraception and

Infertility Loan Repayment Program; 93.864,

Population Research for Mothers and

Children; 93.929, Center for Medical

Rehabilitation Research, National Institutes

of Health, HHS)

Dated: October 25, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–28098 Filed 11–1–00; 8:45 am]

BILLING CODE 4110–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c0(6), title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Child Health and Human Development

Special Emphasis Panel.

Date: November 30, 2000.

Time: 10 AM to 5 PM.

Agenda: To review and evaluate grant

applications.

Place: 5520 Wisconsin Avenue, Chevy

Chase, MD 20815.

Contact Person: Robert H. Stretch, PhD,

Scientific Review Administrator, Division of

Scientific Review, National Institute of Child

Health and Human Development, NIH, 6100

Executive Blvd., Room 5E01, MSC 7510,

Bethesda, MD 20892, (301) 435–6912.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.209, Contraception and

Infertility Loan Repayment Program; 93.864,

Population Research; 93.865, Research for